Journal: Clinical Cancer Research

Article Title: Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

doi: 10.1158/1078-0432.ccr-08-1144

Figure Lengend Snippet: Fig. 5. Imatinib mesylate inhibits STAT phosphorylation. Phospho-STAT1and STAT3 are reduced in M6 and GIST882 cells as a function of imatinib mesylate concentration at 2 and 72 h, respectively (A). Imatinib mesylate inhibits phosphorylation of p70S6K, showing cumulative effects from several upstream pathways. Phospho-S6, a key translational regulator, is also reduced in imatinib mesylate-treated M6 and GIST882 cells following 2 h exposure (B).

Article Snippet: The following antibodies were used: KIT and BCL-2 (DakoCytomation); phospho-KIT (pY703; Biosource International); total AKT/protein kinase B, phosphoAKT/protein kinase B (Ser473), total mammalian target of rapamycin (mTOR), phospho-mTOR (Ser2448), phospho-70S6K (Thr389), total p70S6K, S6 ribosomal protein (5G10), phospho-S6 ribosomal protein (Ser240/Ser244), phospho-STAT3 (Tyr705), caspase-3, and caspase-9 (Cell Signaling Technology); phospho-STAT1 (pY701) and horseradish peroxidase-conjugated secondary antibody (Invitrogen); total p44/42 mitogen-activated protein kinase, phospho-p44/42 mitogen-activated protein kinase (Thr202/Tyr204), MCL-1, cyclin D1, cyclin E, proliferating cell nuclear antigen (PC10), STAT1, and STAT3 (Santa Cruz Biotechnology); survivin (Novus Biologicals); actin (Sigma); and livin/ML-IAP (Active Motif).

Techniques: Phospho-proteomics, Concentration Assay

Journal: The Journal of nutrition

Article Title: Dairy and Dairy Alternative Supplementation Increase Integrated Myofibrillar Protein Synthesis Rates, and Are Further Increased when Combined with Walking in Healthy Older Women.

doi: 10.1093/jn/nxab358

Figure Lengend Snippet: FIGURE 5 Total protein content of canonical anabolic signaling factors in healthy older women. Box and whisker plots showing the relative protein content of mTOR, p70S6K, rpS6, and 4E-BP1. The horizontal line within the boxes depicts of the median of each group, and the cross the mean. Upper and lower edges of the box represent the 75th and 25th quartiles, respectively. Upper and lower whiskers represent the maximum and minimum values, respectively. Data were analyzed using a linear mixed-effects model. Data that do not share a common letter are significantly different from each other (P ≤0.05). Insets above each box and whisker plot show representative blots at each phase of the study for 1 participant, as well as the associated standard curve from the same gel (5, 10, and 15 μg of protein loaded). Panel E shows a representative membrane image taken after proteins were transferred from gel to membrane and panel F shows representative images of each time point and calibration curve standards. Sample sizes: AB (BL, n = 8; P1, n = 8; P2, n = 7; P3, n = 7), SM (BL, n = 7; P1, n = 6; P2, n = 7; P3, n = 6), WM (BL, n = 7; P1, n = 7; P2, n = 6; P3, n = 7). AB, almond beverage; BL, baseline (day 0); P1, End of Phase 1 (day 4); P2, End of Phase 2 (day 7); P3, End of Phase 3 (day 10); mTOR, mechanistic target of rapamycin; p70S6K, p70 ribosomal protein S6 kinase; rpS6, ribosomal protein S6; 4E-BP1, Eukaryotic translation initiation factor 4E-binding protein 1; RAU, relative arbitrary units; SM, skim milk; WM, whole milk.

Article Snippet: Primary antibodies against mechanistic target of rapamycin (mTOR) (1:1000, 7C10, Cat #2983S), p70S6K (1:1000, 49D7, Cat #2708S), rpS6 (1:1000, 5G10, Cat #2217S), and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) (1:1000, 53H11, Cat# 9644S) and horseradish peroxidase (HRP)-conjugated secondary antibody (1:10,000, Cat #7074S) were purchased from Cell Signaling Technologies.

Techniques: Whisker Assay, Membrane, Binding Assay